US Pharma MarketingThe post EyePoint’s Duravyu falls short to Eylea in Phase III trial appeared first on Clinical Trials Arena.
EyePoint’s Duravyu falls short to Eylea in Phase III trial
GlobalData highlighted EyePoint’s Duravyu as a notable drug set to enter the wet AMD market by 2034. The post EyePoint’s Duravyu falls short to Eylea in Phase III trial appeared first on Clinical Trials Arena .
GlobalData highlighted EyePoint’s Duravyu as a notable drug set to enter the wet AMD market by 2034.
Source: Clinical Trials Arena